Suppr超能文献

纳米颗粒的原位细胞搭乘递药。

In situ cellular hitchhiking of nanoparticles for drug delivery.

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA.

Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA; Translational Oncology Program, University of Illinois Cancer Center, Chicago, IL 60612, USA.

出版信息

Adv Drug Deliv Rev. 2024 Jan;204:115143. doi: 10.1016/j.addr.2023.115143. Epub 2023 Nov 24.

Abstract

Since the inception of the concept of "magic bullet", nanoparticles have evolved to be one of the most effective carriers in drug delivery. Nanoparticles improve the therapeutic efficacy of drugs offering benefits to treating various diseases. Unlike free drugs which freely diffuse and distribute through the body, nanoparticles protect the body from the drug by reducing non-specific interactions while also improving the drug's pharmacokinetics. Despite acquiring some FDA approvals, further clinical application of nanoparticles is majorly hindered by its limited ability to overcome biological barriers resulting in uncontrolled biodistribution and high clearance. The use of cell-inspired systems has emerged as a promising approach to overcome this challenge as cells are biocompatible and have improved access to tissues and organs. One of such is the hitchhiking of nanoparticles to circulating cells such that they are recognized as 'self' components evading clearance and resulting in site-specific drug delivery. In this review, we discuss the concept of nanoparticle cellular hitchhiking, highlighting its advantages, the principles governing the process and the challenges currently limiting its clinical translation. We also discuss in situ hitchhiking as a tool for overcoming these challenges and the considerations to be taken to guide research efforts in advancing this promising technology.

摘要

自“神奇子弹”概念诞生以来,纳米颗粒已发展成为药物递送中最有效的载体之一。纳米颗粒通过减少非特异性相互作用来提高药物的治疗效果,同时改善药物的药代动力学。与自由扩散和分布在体内的游离药物不同,纳米颗粒通过减少非特异性相互作用来保护身体免受药物侵害,同时改善药物的药代动力学。尽管已经获得了一些 FDA 的批准,但纳米颗粒的进一步临床应用主要受到其克服生物屏障能力的限制,导致不受控制的生物分布和高清除率。利用受细胞启发的系统已成为克服这一挑战的一种很有前途的方法,因为细胞具有生物相容性,并能更好地进入组织和器官。其中之一是将纳米颗粒搭便车到循环细胞中,使其被识别为“自身”成分,从而逃避清除并实现靶向药物递送。在这篇综述中,我们讨论了纳米颗粒细胞搭便车的概念,强调了其优势、指导该过程的原则以及目前限制其临床转化的挑战。我们还讨论了原位搭便车作为克服这些挑战的工具,以及在推进这一有前途的技术方面需要考虑的因素。

相似文献

1
In situ cellular hitchhiking of nanoparticles for drug delivery.纳米颗粒的原位细胞搭乘递药。
Adv Drug Deliv Rev. 2024 Jan;204:115143. doi: 10.1016/j.addr.2023.115143. Epub 2023 Nov 24.
3
Cell-based carrier for targeted hitchhiking delivery.基于细胞的载体用于靶向搭便车传递。
Drug Deliv Transl Res. 2022 Nov;12(11):2634-2648. doi: 10.1007/s13346-022-01149-y. Epub 2022 May 2.
5
Cell-mediated nanoparticle delivery systems: towards precision nanomedicine.细胞介导的纳米颗粒递药系统:迈向精准纳米医学。
Drug Deliv Transl Res. 2024 Nov;14(11):3032-3054. doi: 10.1007/s13346-024-01591-0. Epub 2024 Apr 13.

引用本文的文献

10
Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma.肽搭乘用于神经胶质瘤中纳米系统的发展。
ACS Nano. 2024 Jul 2;18(26):16359-16394. doi: 10.1021/acsnano.4c01790. Epub 2024 Jun 11.

本文引用的文献

7
Cell-based relay delivery strategy in biomedical applications.基于细胞的中继递药策略在生物医学中的应用。
Adv Drug Deliv Rev. 2023 Jul;198:114871. doi: 10.1016/j.addr.2023.114871. Epub 2023 May 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验